Combinations containing TAF and cobicistat linked to physical depression symptoms in women with HIV

Women with HIV taking antiretroviral combinations containing tenofovir alafenamide (TAF) and a cobicistat-boosted protease inhibitor or integrase inhibitor were more likely to experience numerous physical symptoms of depression than women taking other antiretroviral regimens, the Women’s Interagency HIV Study reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) in Seattle.

The study investigators say their findings suggest that doctors need to look at drug combinations rather than individual antiretrovirals when considering whether HIV medication might be causing or contributing to the physical symptoms of depression.

Read the full story at Aidsmap.

Source: https://www.aidsmap.com/news/feb-2023/combinations-containing-taf-and-cobicistat-linked-physical-depression-symptoms-women